Eluent solution

Abstract

The present invention provides a novel method for the preparation of .sup.18F-fluoride (.sup.18F) for use in radiofluorination reactions. The method of the invention finds use especially in the preparation of .sup.18F-labelled positron emission tomography (PET) tracers. The method of the invention is particularly advantageous where bulk solutions are prepared and stored in prefilled vials rather than being freshly prepared on the day of synthesis. Also provided by the present invention is a radiofluorination reaction which comprises the method of the invention, as well as a cassette for use in carrying out the method of the invention and/or the radiofluorination method of the invention on an automated radiosynthesis apparatus.

Claims

1. A method for preparation of an an [.sup.18F]FACBC radiotracer on a cassette within an automated radiosynthesis apparatus, wherein said method comprises: (i) trapping an aqueous solution of .sup.18F.sup.− onto an anion exchange column on the cassette of the automated radiosynthesis apparatus; (ii) passing an eluent solution from a bulk solution or a prefilled vial of the cassette through said anion exchange column on which said .sup.18F— is adsorbed to obtain an .sup.18F.sup.− eluent, the eluent solution comprising a mixture of potassium carbonate and 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane in an aqueous alkanol solvent and being devoid of acetonitrile; (iii) drying the .sup.18F.sup.− eluent eluted from the column in step (ii) in the presence of acetonitrile; (iv) reacting the 18F— with a precursor followed by removal of protecting groups in the automated radiosynthesis apparatus to obtain the [.sup.18F]FACBC; and (v) purification of the [.sup.18F]FACBC using solid phase extraction; wherein said eluent solution is capable of being (i) prepared in bulk and (ii) stored in a plurality of vials prior to use, thereby affording a consistent percentage radiochemical yield of the [.sup.18F]FACBC when used in a plurality of subsequent radiofluorination reactions over time.

2. The method as defined in claim 1, wherein said anion exchange column is a quaternary methylammonium (QMA) column.

3. The method as defined in claim 1, wherein the alkanol solvent is aqueous methanol having a ratio of methanol to water greater than about 79.5:20.5.

4. The method as defined in claim 1, wherein the alkanol solvent is aqueous methanol having a ratio of methanol to water greater than 90:10.

5. A method for preparation of an [.sup.18F]FACBC radiotracer on a cassette within an automated radiosynthesis apparatus, wherein said method comprises: (i) trapping an aqueous solution of .sup.18F.sup.− onto a quaternary methylammonium (QMA) column on the cassette of the automated radiosynthesis apparatus; (ii) passing an eluent solution from a bulk solution or a prefilled vial of the cassette through said anion exchange column on which said .sup.18F— is adsorbed to obtain an .sup.18F.sup.− eluent, the eluent solution comprising a mixture of 4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane and K.sub.2CO.sub.3 in an aqueous methanol solvent and being devoid of acetonitrile; (iii) drying the .sup.18F.sup.− eluent eluted from the column in step (ii) in the presence of acetonitrile; (iv) reacting the 18F— with a precursor followed by removal of protecting groups in the automated radiosynthesis apparatus to obtain the [.sup.18F]FACBC; and (v) purification of the [.sup.18F]FACBC in the automated radiosynthesis apparatus using solid phase extraction; wherein said eluent solution is capable of being (i) prepared in bulk and (ii) stored in a plurality of vials prior to use, thereby affording a consistent percentage radiochemical yield of the [.sup.18F]FACBC when used in a plurality of subsequent radiofluorination reactions over time.

6. The method as defined in claim 5, wherein the aqueous methanol solvent has ratio of methanol to water greater than about 79.5:20.5.

7. The method as defined in claim 5, wherein the aqueous methanol solvent has ratio of methanol to water greater than 90:10.

8. The method as defined in claim 1, wherein the eluent solution is provided in a prefilled vial of the cassette.

9. The method as defined in claim 5, wherein the eluent solution is provided in a prefilled vial of the cassette.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 is a graph showing acetamide generated in [.sup.18F]FACBC and [.sup.18F]FDG eluent vials during storage at 5° C., 25° C. and 40° C. (n=2−3).

(2) FIG. 2 is a graph showing acetate generated in [.sup.18F]FACBC and [.sup.18F]FDG eluent vials during storage at 5° C., 25° C. and 40° C. (n=2-3).

(3) FIG. 3 shows the RCY of [.sup.18F]FACBC after eluent stored at 30° C. (.circle-solid.), 40° C. (.diamond-solid.) and RCY of [.sup.18F]FDG after eluent stored at eluent at 25° C. (.square-solid.), 40° C. (.box-tangle-solidup.).

(4) FIG. 4 illustrates the RCY of [.sup.18F]FACBC after eluent with methanol (MeOH) stored at 30° C. (.box-tangle-solidup.), 50° C. (.circle-solid.) and RCY of [.sup.18F]FDG after eluent with acetonitrile (MeCN) stored at eluent at 30° C. (.diamond-solid.), 40° C. (.square-solid.).

DETAILED DESCRIPTION OF THE INVENTION

(5) In one aspect the present invention provides a method for preparation of .sup.18F.sup.− for use in a radiofluorination reaction wherein said method comprises: (i) trapping an aqueous solution of .sup.18F.sup.− onto an ion exchange column; and, (ii) passing an eluent solution through said ion exchange column on which said .sup.18F.sup.− is adsorbed to obtain an .sup.18F.sup.− eluent, wherein said eluent solution comprises a cationic counterion in a suitable solvent with the proviso that said eluent solution does not comprise acetonitrile.

(6) The term “radiofluorination” in the context of the present invention refers to a radiochemical reaction for the production of an .sup.18F-labelled compound wherein .sup.18F.sup.− is reacted with a precursor compound comprising a substituent suitable for nucleophilic substitution with .sup.18F.sup.−.

(7) The term “trapping” an aqueous solution of .sup.18F.sup.− onto an ion exchange column refers to the process by which .sup.18F.sup.− is retained on the ion exchange column. A suitable “ion exchange cartridge” in the context of the present invention is a solid-phase extraction (SPE) cartridge that retains .sup.18F.sup.− and allows H.sub.2.sup.18O to pass through when an aqueous solution from the nuclear reaction .sup.18O(p,n).sup.18F is passed through. Preferably, said ion-exchange cartridge is an anion exchange cartridge, most preferably a quaternary methylammonium (QMA) cartridge.

(8) The term “.sup.18F.sup.− eluent” refers to the solution comprising .sup.18F.sup.− and the eluent solution obtained when the eluent solution is passed through the ion exchange column.

(9) Said “eluent: solution” is free of acetonitrile, and preferably consists of said cationic counterion in said suitable solvent.

(10) A “cationic counterion” in the context of the present invention is a positively-charged counterion that acts to improve the reactivity of .sup.18F.sup.− when combined therewith. Examples of suitable cationic counterions for use in the method of the present invention include large but soft metal ions such as rubidium, caesium, potassium complexed with a cryptand, or tetraalkylammonium salts. A preferred cationic counterion is a metal complex of a cryptand, most preferably wherein said metal is potassium and wherein said cryptand is Kryptofix 222.

(11) The “suitable solvent” for the eluent solution docs not comprise any acetonitrile. Preferably, said suitable solvent is an alkanol, and is preferably ethanol or methanol, most preferably methanol. Said suitable solvent is either 100% alkanol, or is alternatively an “aqueous solution of an alkanol”. For example said suitable solvent may comprise a ratio of alkanol:water in the range 60:40 to 100:0, preferably in the range 80:20 to 100:0 and most preferably 90:10 to 100:0. A certain amount of water can help with consistent elution of .sup.18F.sup.− but it is preferable to have as little water as possible as the percentage of water is directly proportional to subsequent drying time.

(12) The method of the invention is most advantageous where the eluent solution is for convenience prepared as a bulk solution and/or in prefilled vials for storage. As noted in the description of the prior art, use of prefilled vials permits more well defined, reliable and reproducible synthesis processes (Hjelstuen et al, Eur J Pharm Biopharm 2011, 78: 307), and prefilled vials can be made with a low bioburden and a documented shelf life, which serves as a better starting point for good manufacturing practice (GMP) quality manufacture compared to manually mixed solutions.

(13) The method of the invention may optionally comprise the additional step: (iii) drying said .sup.18F.sup.− eluted from said column in step (ii).

(14) The term “drying” refers to the evaporation of the suitable solvent (as described above) to result in anhydrous .sup.18F.sup.−. This drying step is suitably carried out by application of heat and/or use of a solvent such as acetonitrile to provide a lower boiling azeotrope.

(15) .sup.18F-labelled PET tracers are conveniently prepared by means of an automated radiosynthesis apparatus. There are several commercially-available examples of such apparatus. An apparatus such as FASTlab™ (GE Healthcare) comprises a disposable cassette in which the radiochemistry is performed, which is fitted to the apparatus to perform the radiosynthesis.

(16) In a preferred embodiment, the method of the present, invention is automated. Most preferably, the method of the present invention is carried out on a cassette suitable for use with an automated radiosynthesis apparatus.

(17) The term “automated” refers to where a process is predominantly carried out using a machine or apparatus, i.e. comprising a minimal number of manual steps.

(18) The term “cassette” refers to a disposable unit in which radiochemistry is performed. The cassette is fitted to an automated synthesis apparatus in order to perform a radiosynthesis and normally includes fluid pathways, a reaction vessel, and ports for receiving reagent vials as well as any solid-phase extraction cartridges used in post-radiosynthetic clean up steps. There are several commercially-available examples of “automated synthesis apparatus”, including TRACERlab™ and FASTlab™ (GE Healthcare Ltd).

(19) In another aspect, the present invention provides a radiofluorination reaction to obtain an .sup.18F-labelled positron emission tomography (PET) tracer wherein said radiofluorination reaction comprises reaction of a precursor compound with .sup.18F.sup.−, wherein said precursor compound may comprise one or more protecting groups, and wherein said .sup.18F.sup.− is obtained by the method as defined herein.

(20) The suitable and preferred embodiments of any features of the method of the invention that are common to the radiofluorination reaction of the invention also apply to the radiofluorination reaction of the invention.

(21) An “.sup.18F-labelled PET tracer” is an .sup.18F-labelled compound that when administered to a subject preferentially binds to a particular target within said subject in order that the target may be imaged by detecting emissions from .sup.18F external to said subject using PET imaging. The term “PET imaging” refers to the nuclear medicine imaging technique that produces a three-dimensional image or picture of functional processes in the body. The technique detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide such as fluorine-18, which is introduced into the body as part of a PET tracer. Three-dimensional images of tracer concentration within the body are then constructed by computer analysis.

(22) A “precursor compound” comprises a non-radioactive derivative of an .sup.18F-labelled PET tracer designed so that chemical reaction with .sup.18F.sup.− occurs site-specifically, can be conducted in the minimum number of steps (ideally a single step) and without the need for significant purification (ideally no further purification), to give the .sup.18F-labelled PET tracer. Such precursor compounds are synthetic and can conveniently be obtained in good chemical purity.

(23) Suitable “protecting groups” are well-known in the art and are discussed in more detail by Theodora W. Greene and Peter G. M. Wuts in “Protective Groups in Organic Synthesis” (Fourth Edition, John Wiley & Sons, 2007).

(24) It will be appreciated by the skilled person that the inventive methods described herein can be applied for the preparation of any .sup.18F-labelled PET tracer that can be prepared using nucleophilic radio fluorination with .sup.18F.sup.− Non-limiting examples of such .sup.18F-labelled PET tracers includes those set out in Table 1 below:

(25) TABLE-US-00001 .sup.18F-labelled PET Tracer Known Nucleophilic Method 2-deoxy-2-[.sup.18F]fluoro-D-glucose ([.sup.18F]- displacement of triflate FDG) [.sup.18F]fluorothymidine ([.sup.18F]-FLT) displacement of nosylate [.sup.18F]fluoronitroimidazole ([.sup.18F]-FMISO) displacement of tosylate 6-[.sup.18F]fluoroDOPA aromatic substitution of nitro [.sup.18F]setoperone aromatic substitution of nitro [.sup.18F]altanserin aromatic substitution of nitro [.sup.18F]N-methylspiperone aromatic substitution of nitro 6-[.sup.18F]fluorodopamine aromatic substitution of 6- nitroperonal (−)6-[.sup.18F]fluoro-norepinephrine aromatic substitution 16α-[.sup.18F]fluoroestradiol displacement of an aliphatic cyclic sulfone [.sup.18F]fleroxacin displacement of mesylate [.sup.18F]fluconazole aromatic Schiemann reaction 1-amino-3-[.sup.18F]fluorocyclobutane-1- displacement of triflate carboxylic acid ([.sup.18F]-FACBC)

(26) The reactions listed in Table 1 above are common general knowledge in the art and are described for example in Chapter 14 of “Fluorine in Medicinal Chemistry and Chemical Biology” (Wiley 2009, Ojima. Ed), Chapter 6 of “Handbook of Radiopharmaceuticals: Radiochemistry and Applications (Wiley 2003, Welch and Redvanley, Eds), Chapter 6 of “Basic Sciences of Nuclear Medicine” (Springer 2011, Khalil, Ed) and in Chapter 10 of “Molecular Imaging: Radiopharmaceuticals for PET and SPECT” (Springer 2009, Vallabhajosula, Ed).

(27) In a preferred embodiment, the .sup.18F-labelled PET tracer is one of [.sup.18F]FDG, [.sup.18F]FMISO, [.sup.18F]FLT and [.sup.18F]FMISO, most preferably [.sup.18F]FDG or [.sup.18F]FACBC, and most especially preferably [.sup.18F]FACBC.

(28) In the experiments reported herein on storage of acetonitrile-based eluent solutions, it was found that the concentration of acetate was 3 times higher during labelling of [.sup.18F]FACBC as compared with [.sup.18F]FDG:

(29) TABLE-US-00002 Volume Acetamide Acetate FASTlab process step (μl) (μg/ml) (μg/ml) [.sup.18F]FACBC synthesis Eluent vial 1105 8700 3100 Reactor before drying 682 7320 2530 Reactor during labelling 1000 3495 1795 End-product 26000 0.2-0.5 nm [.sup.18F]FDG synthesis Eluent vial 825 8700 3100 Reactor before drying 377 6265 2120 Reactor during labelling 1600 844 597 End-product 15000 0.2-0.4 nm

(30) As compared with [.sup.18F]FDG, in the synthesis of [.sup.18F]FACBC more eluent (1105 μl vs. 825 μl) and hence more acetate is introduced to the reaction vessel. The difference is enhanced during labelling because the volume used for labelling for [.sup.18F]FACBC is smaller (1.0 ml vs. 1.6 ml). These coincidental factors like smaller volume of eluent and larger volume of labelling solvent made the synthesis of [.sup.18F]FDG as described herein more resistant to eluent storage compared to the [.sup.18F]FACBC reaction. It may well be that [.sup.18F]FDG synthesis setups elsewhere could be more prone to eluent storage. This could be equally true in the case of other .sup.18F-labelled PET tracers such as those listed above, and the present invention is thereby a solution that is easy to implement and is not detrimental on the quality of the eventual product.

(31) It is most preferred that the radiofluorination reaction of the invention is automated, most preferably on an automated radiosynthesis apparatus as suitable and preferably described above.

(32) In yet another aspect, the present invention provides a cassette for carrying out the radiofluorination reaction on an automated synthesis apparatus wherein said cassette comprises: (i) an anion exchange column suitable for trapping an aqueous solution of .sup.18F.sup.−, wherein said anion exchange column is as defined herein; (ii) a first vessel containing an eluent solution as defined herein; (iii) a second vessel containing a precursor compound which upon reaction with .sup.18F results in an .sup.18F-labelled PET tracer as defined herein, wherein said .sup.18F.sup.− is obtained by the method as defined herein.

(33) The suitable and preferred embodiments of any features of the method of the invention and/or the radiofluorination reaction of the invention that are common to the cassette of the invention also apply to the cassette of the invention.

BRIEF DESCRIPTION OF THE EXAMPLES

(34) Example 1 describes an analysis of prior art eluent solutions that were stored.

(35) Example 2 describes the synthesis of [.sup.18F]FACBC and [.sup.18F]FDG with stored vs. freshly-prepared prior art eluent.

(36) Example 3 describes the synthesis of [.sup.18F]FACBC with stored vs. freshly-prepared eluent of the present invention.

LIST OF ABBREVIATIONS USED IN THE EXAMPLES

(37) ATR attenuated total reflectance DTGS deuterated triglycine sulphate [.sup.18F]FACBC 1-amino-3-[.sup.18F]fluorocyclobutane-1-carboxylic acid [.sup.18F]FDG 2-deoxy-2-[.sup.18F]fluoro-D-glucose FT-IR Fourier transform infrared K222 Kryptofix 222 MeCN acetonitrile MeOH methanol QMA quaternary methyl ammonium RCY radiochemical yield SPE solid-phase extraction TLC thin layer chromatography UV ultraviolet

EXAMPLES

(38) All reagents and solvents were purchased from Merck and used without further purification. The [.sup.18F]FDG precursor; 1,3,4,6-Tetra-O-acetyl-2-O-trifluoromethancsulfonyl-β-D-mannopyranose was purchased from ABX while the [.sup.18F]FACBC precursor; Syn-1-(N-(tert-butoxycarbonyl)amino)-3-[[(trifluoromethyl)sulfonyl]oxy]-cyclobutane-1-carboxylic acid ethyl ester was obtained from GE Healthcare. The Oasis HLB plus cartridge and the Sep-Pak cartridges: QMA light Plus (K.sub.2CO.sub.3 form), tC18 light. Alumina N light were purchased from Waters (Milford, Mass., USA). A Capintec Nal ion chamber was used for all radioactive measurements (model CRC15R). Radio-thin layer chromatography (radio-TLC) was performed on a Packard instant imager using pre-coated plates of silica gel (Merck 60F.sub.254).

Example 1

Storage of Prior Art Eluent Solutions

(39) 3.0 ml FASTlab eluent vials consisting of type-1 borosilicate glass (FIOLAX, MGlas AG, Münnerstadt, Germany), capped with a chlorobutyl stopper coated with Fluorotec® (West) and sealed with an aluminium cap after filling the eluent solution were used for the storage of two eluent solutions optimized for either [.sup.18F]FACBC or [.sup.18F]FDG synthesis

(40) The eluent solutions were as follows:

(41) TABLE-US-00003 Eluent composition [.sup.18F]FACBC [.sup.18F]FDG K222 53.0 mg/ml 53.0 mg/ml K.sub.2CO.sub.3 7.3 mg/ml 9.5 mg/ml MeCN:H.sub.2O 79.5:20.5 (v/v) 79.5:20.5 (v/v) Fill volume 1.105 ml 0.825 ml

(42) The vials were stored in darkness in an up-right position using storage temperatures of 5, 25, 30, 40 and 50° C. Both eluents were stored over a nine-month period, during which time levels of acetamide and acetate were measured. Acetamide was quantified by infrared spectroscopy using a Perkin Elmer Spectrum 2000 Explorer FT-IR spectrometer with a DTGS detector and a single reflection diamond ATR (DuraSamplIR II from SensIR Technologies). Acetate was quantified by liquid chromatography with UV detection (Agilent 1100 series).

(43) Notable levels (mg/ml) of acetamide and acetate were generated during a nine-month period of storage as seen in FIG. 1 (acetamide generated in FACBC and FDG eluent vials during storage at 5° C., 25° C. and 40° C.; n=2-3) and FIG. 2 (acetate generated m FACBC and FDG eluent vials during storage at 5° C., 25° C. and 40° C. n=2-3).

Example 2

Synthesis of [.SUP.18.F]FACBC and [.SUP.18.F]FDG with Stored vs. Freshly-prepared Prior Art Eluent

(44) The synthesis of [.sup.18F]FACBC and [.sup.18F]FDG was tested with both freshly prepared and stored eluents to investigate the impact of generated levels of acetamide and ammonium acetate on the RCY.

(45) No-carrier-added [.sup.18F]fluoride was produced via the .sup.18O(p,n).sup.18F nuclear reaction on a GE PETtrace 6 cyclotron (Norwegian Cyclotron Centre, Oslo). Irradiations were performed using a dual-beam, 30 μA current on two equal Ag targets with HAVAR foils using 16.5 MeV protons. Each target contained 1.6 ml of ≥96% [.sup.18O]water (Marshall Isotopes). Subsequent to irradiation and delivery to a hotcell, each target was washed with 1.6 ml of [.sup.16O]water (Merck, water for GR analysis), giving approximately 2-5 Gbq in 3.2 ml of [.sup.16O]water.

(46) All radiochemistry was performed on a commercially available GE FASTlab™ with single-use cassettes. Each cassette is built around a one-piece-moulded manifold with 25 three-way stopcocks, all made of polypropylene. Briefly, the cassette includes a 5 ml reactor (cyclic olefin copolymer), one 1 ml syringe and two 5 ml syringes, spikes for connection with five prefilled vials, one water bag (100 ml) as well as various SPE cartridges and filters. Fluid paths are controlled with nitrogen purging, vacuum and the three syringes. The fully automated system is designed for single-step fluorinations with cyclotron-produced [.sup.18F]fluoride. The FASTlab was programmed by the software package in a step-by-step time-dependent sequence of events such as moving the syringes, nitrogen purging, vacuum, and temperature regulation. Synthesis of [.sup.18F]FDG and [.sup.18F]FACBC were customized on separate cassettes, but both synthesis followed the three general steps: (a) [.sup.18F]fluorination, (b) hydrolysis of protection groups and (c) SPE purification.

Prior Art Synthesis of [.SUP.18.F]FDG

(47) Vial A contained K222 (43.7 mg, 117 μmol), K.sub.2CO.sub.3 (7.8 mg, 56.7 μmol) in 79.5% (v/v) MeCN.sub.(aq) (825 μl). Vial B contained the precursor (39 mg, 81.2 μmol) in 2.0 ml of MeCN with 1700 ppm water. Vial C contained of MeCN (4.1 ml). Vial D contained 2 M NaOH (4.1 ml). Vial E contained 2.3 M phosphoric acid (4.1 ml). Aqueous [.sup.18F]fluoride (1 ml, 100-200 Mbq) was passed through the QMA and into the .sup.18O—H.sub.2O recovery vial. The trapped [.sup.18F]fluoride was eluted into the reactor using eluent from vial A (450 μl) and then concentrated to dryness by azeotropic distillation with acetonitrile (80 μl, vial C). Approximately 1.6 ml of precursor solution (corresponds to 31.2 mg; 65 μmol precursor) from vial B was added to the reactor and heated at 125° C. for 2 min. The reaction mixture was diluted with water and sent through the tC18 cartridge. Reactor was washed with water and sent through the tC18 cartridge. The labelled intermediate, fixed on the tC18 cartridge was first washed with water, then incubated with 2M NaOH (2.0 ml) for 2 min. The crude mixture was mixed with water (1.5 ml) and 2.3 M phosphoric acid (1.5 ml) and passed through the HLB and Alumina cartridges into the product vial made of glass (30 ml). Water (9 ml) was then sent through the HLB and Alumina cartridges and into the product vial. The purified formulation of [.sup.18F]FDG contained a Final volume of 15 ml. Radiochemical purity was tested by radio-TLC using a mixture of MeCN:H.sub.2O (95:5) as the mobile phase. The radiochemical yield (RCY) was expressed as the amount of radioactivity in the [.sup.18F]FDG fraction divided by the total used [.sup.18F]fluoride activity (decay corrected). Total synthesis time was 22 min.

Prior Art Synthesis of [.SUP.18.F]FACBC

(48) Vial A contained K.sub.222 (58.8 mg. 156 μmol), K.sub.2CO.sub.3 (8.4 mg, 60.8 μmol) in 79.5% (v/v) MeCN(aq) (1105 μl). Vial B contained 4 M HCl (2.0 ml). Vial C contained MeCN (4.1 ml). Vial D contained the precursor (48.4 mg, 123.5 μmol) in its dry form (stored at −20° C. until cassette assembly). Vial E contained 2 M NaOH (4.1 ml). The 30 ml product collection glass vial was filled with 200 mM citrate buffer (10 ml). Aqueous [.sup.18F]fluoride (1-1.5 ml, 100-200 Mbq) was passed through the QMA and into the .sup.18O—H.sub.2O recovery vial. The QMA was then flushed with MeCN and sent to waste. The trapped [.sup.18F]fluoride was eluted into the reactor using eluent from vial A (730 μl) and then concentrated to dryness by azeotropic distillation with acetonitrile (80 μl, vial C). Approximately 1.7 ml of MeCN was mixed with precursor in vial D from which 1.0 ml of the dissolved precursor (corresponds to 28.5 mg, 72.7 mmol precursor) was added to the reactor and heated for 3 min at 85° C. The reaction mixture was diluted with water and sent through the tC18 cartridge. Reactor was washed with water and sent through the tC18 cartridge. The labelled intermediate, fixed on the tC18 cartridge was washed with water, and then incubated with 2 M NaOH (2.0 ml) for 5 min. The labelled intermediate (without the ester group) was eluted off the tC18 cartridge into the reactor using water. The BOC group was hydrolysed by adding 4 M HCl (1.4 ml) and heating the reactor for 5 min at 60° C. The reactor content with the crude [.sup.18F]FACBC was sent through the HLB and Alumina cartridges and into the 30 ml product vial. The HLB and Alumina cartridges were washed with water (9.1 ml total) and collected in the product vial. Finally, 2 M NaOH (0.9 ml) and water (2.1 ml) was added to the product vial, giving the purified formulation of [.sup.18F]FACBC with a total volume of 26 ml. Radiochemical purity was measured by radio-TLC using a mixture of MeCN:MeOH:H.sub.2O:CH.sub.3COOH (20:5:5:1) as the mobile phase. The radiochemical yield (RCY) was expressed as the amount of radioactivity in the [.sup.18F]FACBC fraction divided by the total used [.sup.18F]fluoride activity (decay corrected). Total synthesis time was 43 min.

(49) Using freshly prepared eluents, RCY of [.sup.18F]FACBC and [.sup.18F]FDG were 62.5%±1.93 (SD), n=4 and 86.8%±1.25 (SD), n=9 respectively.

(50) When the FACBC eluent was stored at 30 or 40° C., a decrease in RCY with increasing storage time was observed as shown in FIG. 3, which shows the RCY of [.sup.18F]FACBC after eluent stored at 30° C. (.circle-solid.), 40° C. (.diamond-solid.) and RCY of [.sup.18F]FDG after eluent stored at eluent at 25° C. (.square-solid.), 40° C. (.box-tangle-solidup.). The RCY of [.sup.18F]FACBC dropped from 62.5% to 44.7% when the FACBC eluent was stored at 30° C. for 12 months and from 62.5% to 33.6% when stored at 40° C. for 6 months. It was therefore observed a negative correlation between degradation of acetonitrile and reduction in RCY of [.sup.18F]FACBC. The RCY for [.sup.18F]FDG was observed to fall from 86.8% to 66.7% for [.sup.18F]FDG when the eluent solution was stored at 50° C. for 3 months (n=3).

Example 3

Synthesis of f [.SUP.18.F]FACBC with Stored vs. Freshly-prepared Eluent of the Present Invention

(51) FACBC eluent vials in which acetonitrile was replaced by methanol was stored for predetermined time points and tested in the synthesis of [.sup.18F]FACBC. FIG. 4 illustrates the RCY of [.sup.18F]FACBC after eluent with MeOH stored at 30° C. (.box-tangle-solidup.), 50° C. (.circle-solid.) and RCY of [.sup.18F]FDG after eluent with MeCN stored at eluent at 30° C. (.diamond-solid.), 40° C. (.square-solid.). While the acetonitrile based eluent resulted in a gradual decrease in RCY with increasing storage time, the RCY remained unchanged with the methanol-based eluent even when stored at 50° C. for 6 months.